David Ge is CEO and co-founder of Apostle Inc (http://apostlebio.com), a biotechnology company in San Jose, California, focused on innovations related to liquid biopsy. Since Feb 2019, Apostle has entered a global partnership with Beckman Coulter Life Sciences to commercialize its Apostle MiniMax cfDNA isolation technology. In 2018, BioSpace listed Apostle Inc as one of the "Top 20 Life Science Startups to Watch". Apostle has also been selected into the Stanford University StartX program. Prior to Apostle, Dr. Ge was President of BioSciKin Co., Ltd., focused on biomedical incubating, investing and licensing. Between 2011 and 2016, he was Director of Bioinformatics at Gilead Sciences (NASDAQ: GILD), where he provided leadership to the corporate bioinformatics department and provided strategic input to the precision medicine infrastructure and process. Between 2008 and 2011, he was appointed as Assistant Professor of Medicine, Biostatistics and Bioinformatics at Duke University School of Medicine, where he was also member of a U.S. NIH NHGRI Special Emphasis Panel. Dr. Ge received his PhD of Biostatistics and Genetic Epidemiology from Chinese Academy of Medical Sciences in 2004 and completed his postdoctoral training at Duke University. He discovered the IL28B genetic variants associated with clinical response to interferon treatment. The work was published in Nature in 2009, received over 3000 citations to date. His work includes co-authoring 5 articles in Nature and 1 in Science, and has received over 19,000 citations. Dr. Ge was named by the U.S. Genome Technology magazine as one of the "rising stars" in 2009 and by the U.K. Phacilitate as one of the "Top 50 Most Influential People in Big Data" in 2015.